From the Division of Neurology (S.F., D.M., T.J., G.S., G.J.), Department of Medicine, and Neuroscience and Mental Health Institute (J.K.-T.), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Neurology. 2022 Sep 27;99(13):e1356-e1363. doi: 10.1212/WNL.0000000000200909. Epub 2022 Jul 5.
Thrombosis is central to the pathogenesis of acute ischemic stroke, with higher thrombin generation being associated with increased stroke risk. The immune system may contribute to thrombin generation in stroke and thus may offer novel strategies for stroke prevention. This study addresses the research question regarding the relationship of thrombin generation to leukocyte gene expression in patients with acute ischemic stroke.
We isolated RNA from whole blood and examined the relationship to thrombin generation capacity in patients with acute ischemic stroke. Due to its effects on thrombin generation, patients on anticoagulants were excluded from the study. The relationship of gene expression with peak thrombin was evaluated by analysis of covariance across peak thrombin quartiles adjusted for sex and age.
In 97 patients with acute ischemic stroke, peak thrombin was variable, ranging from 252.0 to 752.4 nM. Increased peak thrombin was associated with differences in thromboinflammatory leukocyte gene expression, including a decrease in ADAM metallopeptidase with thrombospondin type 1 motif 13 and an increase in nuclear factor κB (NF-κB)-activating protein, protein disulfide isomerase family A member 5, and tissue factor pathway inhibitor 2. Pathways associated with peak thrombin included interleukin 6 signaling, thrombin signaling, and NF-κB signaling. A linear discriminant analysis model summarizing the immune activation associated with peak thrombin in a first cohort of stroke could distinguish patients with low peak thrombin from high peak thrombin in a second cohort of 112 patients with acute ischemic stroke.
The identified genes and pathways support a role of the immune system contributing to thrombus formation in patients with stroke. These may have relevance to antithrombotic strategies for stroke prevention.
血栓形成是急性缺血性脑卒中发病机制的核心,较高的凝血酶生成与增加的卒中风险相关。免疫系统可能会促进脑卒中患者的凝血酶生成,因此可能为卒中预防提供新的策略。本研究旨在探讨急性缺血性脑卒中患者凝血酶生成与白细胞基因表达之间的关系。
我们从全血中分离 RNA,并研究其与急性缺血性脑卒中患者凝血酶生成能力的关系。由于抗凝治疗对凝血酶生成的影响,本研究排除了正在接受抗凝治疗的患者。通过分析协方差,根据性别和年龄对各四分位峰值凝血酶进行调整,评估基因表达与峰值凝血酶之间的关系。
在 97 例急性缺血性脑卒中患者中,峰值凝血酶变化范围较大,为 252.0 至 752.4 nM。较高的峰值凝血酶与血栓炎症性白细胞基因表达的差异相关,包括 ADAM 金属蛋白酶与 1 型血小板反应蛋白域 13 的减少和核因子 κB(NF-κB)激活蛋白、蛋白二硫键异构酶家族 A 成员 5 和组织因子途径抑制剂 2 的增加。与峰值凝血酶相关的通路包括白细胞介素 6 信号通路、凝血酶信号通路和 NF-κB 信号通路。在脑卒中患者的第一队列中,一个概括了与峰值凝血酶相关的免疫激活的线性判别分析模型可以区分低峰值凝血酶患者和高峰值凝血酶患者。在 112 例急性缺血性脑卒中患者的第二队列中,该模型也具有区分作用。
所鉴定的基因和通路支持免疫系统在脑卒中患者血栓形成中的作用。这些可能与抗血栓形成策略预防脑卒中有关。